As one of the leading vaccine developers, GSK is keen to facilitate the exchange of intellectual know-how between the 2,000 scientists at its R&D sites in Rixensart (Belgium), Rockville (Maryland ...

As a leading vaccine developer, GSK wants to combine the skills of its 2,000 scientists at R&D sites in Rixensart (Belgium), Rockville (Maryland, USA) and Siena (Italy), with the ideas and ...

GSK has been ramping up its manufacturing for Benlysta in anticipation of the new approval, including in-house capacity at its Rockville plant in Maryland, US, and through a contract manufacturing ...